Pharma BD Deal Intelligence
King expects the transaction to be accretive to earnings immediately upon closing... and will add approximately 3% to 4% to projected earnings per share for…
All-stock deal valued at announcement around $3.4B (1.5 King shares per Jones share); ~half of Jones revenue came from thyroid franchise (Levoxyl, Tapazole,…
Most significant 2000 purchases were Levoxyl, Thrombin and Cytomel; thyroid franchise funded by Altace cash flow and became core to King's branded specialty…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
King Pharmaceuticals announced an all-stock acquisition of Jones Pharma valued at ~$3.4B at announcement (recorded as ~$2.4B pooling at close). Each Jones share exchanged for 1.5 King shares. Brought thyroid franchise and an experienced specialty sales force. Closed Aug 31, 2000.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| King Pharmaceuticals Inc. / Jones Pharma Incorporated (this deal) | 2000 | $3.4B | 54 |
| King Pharmaceuticals Inc. / Bristol-Myers Squibb (Corgard/Corzide/Delestrogen/Florinef rights) | 2001 | $285M | 51 |
| King Pharmaceuticals Inc. / Aventis Pharmaceuticals (Intal/Tilade/Synercid rights) | 2002 | $275M | 26 |
| Novo Nordisk A/S / Emisphere Technologies | 2020 | $1.4B | 90 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Novo Holdings A/S / Catalent (manufacturing sites) | 2024 | $11.0B | 81 |
← Browse all deals · How we score deals
More: 2000 deals · King Pharmaceuticals Inc. deals · Metabolic deals